Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor‐1

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical and Experimental Immunology

• Publication date

  2018-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/cei.13090PMID 29235095PMCID PMC5842402
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020cited by this paper
• IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).

  2017cited by this paper
• Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?

  2016cited by this paper
• Ten years of anti-vascular endothelial growth factor therapy

  2016cited by this paper
• Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma

  2016cited by this paper
• Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials.

  2016cited by this paper
• VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

  2015cited by this paper
• Computational systems biology approaches to anti-angiogenic cancer therapeutics.

  2015cited by this paper
• The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.

  2015cited by this paper
• IL-4 regulates specific Arg-1(+) macrophage sFlt-1-mediated inhibition of angiogenesis.

  2015cited by this paper
• Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers

  2015cited by this paper
• Temporal phenotypic features distinguish polarized macrophages in vitro

  2015cited by this paper
• Tumor-associated macrophages in diffuse large B-cell lymphoma

  2015cited by this paper
• γδ T cells for cancer immunotherapy

  2014cited by this paper
• VEGF targets the tumour cell

  2013cited by this paper
• Fcγ Receptor-induced Soluble Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) Production Inhibits Angiogenesis and Enhances Efficacy of Anti-tumor Antibodies*

  2013cited by this paper
• VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer

  2013cited by this paper
• VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2

  2012cited by this paper
• Tumor-promoting Versus Tumor-antagonizing Roles of &ggr;&dgr; T Cells in Cancer Immunotherapy: Results From a Prospective Phase I/II Trial

  2012cited by this paper
• Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells

  2012cited by this paper
• Identification of a Novel Proinflammatory Human Skin-Homing Vγ9Vδ2 T Cell Subset with a Potential Role in Psoriasis

  2011cited by this paper
• Protective and pathogenic functions of macrophage subsets

  2011cited by this paper
• Immunity, inflammation, and cancer.

  2010cited by this paper
• VEGF Blockade Inhibits Lymphocyte Recruitment and Ameliorates Immune-Mediated Vascular Remodeling

  2010cited by this paper
• Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo.

  2010cited by this paper
• Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

  2010cited by this paper
• IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia.

  2010cited by this paper
• Soluble VEGFR‐2: an antilymphangiogenic variant of VEGF receptors

  2010cited by this paper
• Tumor‐infiltrating IL‐17‐producing γδ T cells support the progression of tumor by promoting angiogenesis

  2010cited by this paper
• A Compartment Model of VEGF Distribution in Humans in the Presence of Soluble VEGF Receptor-1 Acting as a Ligand Trap

  2009cited by this paper
• Cutting Edge: Vascular Endothelial Growth Factor-Mediated Signaling in Human CD45RO+ CD4+ T Cells Promotes Akt and ERK Activation and Costimulates IFN-γ Production

  2009cited by this paper
• Expression of Soluble Vascular Endothelial Growth Factor Receptor-1 in Human Monocyte-Derived Mature Dendritic Cells Contributes to Their Antiangiogenic Property1

  2009cited by this paper
• Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.

  2009cited by this paper
• Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.

  2009cited by this paper
• Tumor angiogenesis.

  2008cited by this paper
• Immune Response of Human Propagated γδ-T-Cells to Neuroblastoma Recommend the Vδ1+ Subset for γδ-T-cell–based Immunotherapy

  2008cited by this paper
• A compartment model of VEGF distribution in blood, healthy and diseased tissues

  2008cited by this paper
• Autocrine VEGF signaling is required for vascular homeostasis.

  2007cited by this paper
• Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients

  2007cited by this paper
• VEGF receptor signalling ? in control of vascular function

  2006cited by this paper
• Phosphostim-Activated γδ T Cells Kill Autologous Metastatic Renal Cell Carcinoma1

  2005cited by this paper
• Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.

  2005cited by this paper
• Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways.

  2004cited by this paper
• Characterization of Tumor Reactivity of Human Vγ9Vδ2 γδ T Cells In Vitro and in SCID Mice In Vivo1

  2004cited by this paper
• GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice.

  2004cited by this paper
• Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors

  2004cited by this paper
• Angiogenesis-Inflammation Cross-Talk: Vascular Endothelial Growth Factor Is Secreted by Activated T Cells and Induces Th1 Polarization

  2004cited by this paper
• Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo.

  2004cited by this paper
• M-CSF Induces Vascular Endothelial Growth Factor Production and Angiogenic Activity From Human Monocytes 1

  2003cited by this paper
• Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

  2003cited by this paper
• Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

  2003cited by this paper
• Proinflammatory functions of vascular endothelial growth factor in alloimmunity.

  2003cited by this paper
• Purified protein derivative of tuberculin upregulates the expression of vascular endothelial growth factor in T lymphocytes in vitro

  2002cited by this paper
• Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration

  2002cited by this paper
• The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies

  2002cited by this paper
• Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.

  2001cited by this paper
• Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma

  2000cited by this paper
• Thrombocytes Are the Major Source for Soluble Vascular Endothelial Growth Factor in Peripheral Blood

  2000cited by this paper
• Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.

  2000cited by this paper
• Vascular endothelial growth factor (VEGF) and its receptors

  1999cited by this paper
• Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up‐regulation by tumour necrosis factor‐alpha (TNF‐α) in synovial fluid

  1999cited by this paper
• Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2.

  1998cited by this paper
• Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.

  1996cited by this paper
• Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR.

  1996cited by this paper
• Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

  1996cited by this paper
• The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities

  1996cited by this paper
• Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis.

  1995cited by this paper
• Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue

  1994cited by this paper
• Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.

  1991cited by this paper
• Differential regulation of lymphokine production by distinct subunits of the T cell interleukin 2 receptor.

  1991cited by this paper

• Fibrin-targeted ROS-scavenging micelles with photothermal and NO delivery for thrombolysis and post-thrombotic vascular remodeling.

  2025cites this paper
• CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma

  2025cites this paper
• Lp-PLA2 in the cancer landscape: From molecular mechanisms to therapeutic potential (Review)

  2025cites this paper
• Exploring the role of granzyme B in subretinal fibrosis of age-related macular degeneration

  2024cites this paper
• Clinical impact of epithelial–mesenchymal transition for cancer therapy

  2024cites this paper
• The alleviated symptoms in ovalbumin‐allergic mice treated with selenium‐enriched tea polysaccharide by modulation of intestinal flora and gut metabolites

  2024cites this paper
• Succinylation modification-mediated upregulation of Sp1 promotes hepatocellular carcinoma cell proliferation

  2024cites this paper
• Preparation of sulfated arabinogalactan-loaded hydrogel for wound healing in mouse burn model.

  2024cites this paper
• CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma

  2023cites this paper
• Landscape of Well-Coordinated Fracture Healing in a Mouse Model Using Molecular and Cellular Analysis

  2023cites this paper
• The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF.

  2023cites this paper
• Recent Advances in the Multifunctional Microneedles: From Design to Cancer Preventing, Diagnosis, and Treatment

  2023cites this paper
• Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney.

  2023cites this paper
• The role of angiogenic growth factors in the immune microenvironment of glioma

  2023cites this paper
• VEGF and its receptors - formation, structure, and role in the organism

  2023cites this paper
• The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors

  2022influential citation
• Curcumin in Combination With Omacetaxine Suppress Lymphoma Cell Growth, Migration, Invasion, and Angiogenesis via Inhibition of VEGF/Akt Signaling Pathway

  2021cites this paper
• Inflammatory cells in tumor microenvironment

  2021cites this paper
• Vincristine-doxorubicin co-loaded artificial low-density lipoproteins towards solid tumours.

  2021cites this paper
• Targeting the Tumor Microenvironment for a More Effective and Efficient Cancer Immunotherapy

  2020cites this paper
• Nonparametric Method for Estimation of Controlled Correlations in Studies of VEGF-Hypoxia Relationship

  2020cites this paper
• Autologous CXCR4+ Hematopoietic Stem Cells Injected Into the Scar Tissue of Chronic Myocardial Infarction Patients Normalizes Tissue Contractility and Perfusion.

  2020cites this paper
• Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy

  2018cites this paper
• Predictive effect of exhaled NO and VEGF expression levels on the severity of bronchial asthma and airway inflammation.

  2018cites this paper
• Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer

  2018cites this paper
• Cross talk between natural killer cells and mast cells in tumor angiogenesis

  2018cites this paper